Else Marit Inderberg
Overview
Explore the profile of Else Marit Inderberg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
623
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Inderberg E, Singh N, Miller R, Arbe-Barnes S, Eriksen H, Lversen B, et al.
Cancer Immunol Immunother
. 2025 Feb;
74(4):115.
PMID: 39998682
FMPV-1 is a component of FMPV-3, an investigational cancer-specific vaccine and being developed to activate anti-cancer T cell responses targeting frameshift mutations of MSI-H cancers. FMPV-1 is designed to activate...
2.
Rosselle L, Leray T, Joaquina S, Caulier B, McCormack E, Gelebart P, et al.
STAR Protoc
. 2024 Dec;
6(1):103529.
PMID: 39739533
Chimeric antigen receptors (CARs) are synthetic molecules composed of an extracellular antigen-binding domain and an intracellular signaling domain, leading to tonic signaling and manufacturing challenges. We present a protocol for...
3.
Safont M, Leitch C, Popa M, Gjerstad M, Caulier B, Inderberg E, et al.
STAR Protoc
. 2024 Dec;
5(4):103522.
PMID: 39673705
Patient-derived xenograft (PDX) models of acute myeloid leukemia (AML-PDX) offer advantages over cell line models by capturing the complexity and heterogeneity of patient-derived samples. Here, we present a protocol for...
4.
Bobrowicz M, Kusowska A, Krawczyk M, Zhylko A, Forcados C, Slusarczyk A, et al.
Oncoimmunology
. 2024 Jun;
13(1):2362454.
PMID: 38846084
Rituximab (RTX) plus chemotherapy (R-CHOP) applied as a first-line therapy for lymphoma leads to a relapse in approximately 40% of the patients. Therefore, novel approaches to treat aggressive lymphomas are...
5.
Caulier B, Joaquina S, Gelebart P, Dowling T, Kaveh F, Thomas M, et al.
Cell Rep Med
. 2024 May;
5(6):101572.
PMID: 38754420
Acute myeloid leukemia (AML) is characterized by the accumulation of immature myeloid cells in the bone marrow and the peripheral blood. Nearly half of the AML patients relapse after standard...
6.
Casey N, Kleinmanns K, Forcados C, Gelebart P, Joaquina S, Lode M, et al.
J Immunother Cancer
. 2024 Apr;
12(4).
PMID: 38604812
Background: Ovarian cancer (OC) is the leading cause of death from gynecologic malignancies in the Western world. Contributing factors include a high frequency of late-stage diagnosis, the development of chemoresistance,...
7.
Maggadottir S, Dueland S, Mensali N, Hamre H, Andresen P, Myhre M, et al.
Mol Ther
. 2024 Apr;
32(6):2021-2029.
PMID: 38582964
We previously demonstrated the antitumor effectiveness of transiently T cell receptor (TCR)-redirected T cells recognizing a frameshift mutation in transforming growth factor beta receptor 2. We here describe a clinical...
8.
Klee C, Villatoro A, Casey N, Inderberg E, Walchli S
Methods Cell Biol
. 2024 Mar;
183:335-353.
PMID: 38548418
Chimeric antigen receptor (CAR) T cells (CAR T) have emerged as a potential therapy for cancer patients. CAR T cells are capable of recognizing membrane proteins on cancer cells which...
9.
Floisand Y, Remberger M, Bigalke I, Josefsen D, Valerhaugen H, Inderberg E, et al.
Leukemia
. 2023 Jul;
37(9):1842-1849.
PMID: 37507426
Intensive induction chemotherapy achieves complete remissions (CR) in >60% of patients with acute myeloid leukemia (AML) but overall survival (OS) is poor for relapsing patients not eligible for allogeneic hematopoietic...
10.
Joaquina S, Forcados C, Caulier B, Inderberg E, Walchli S
Front Bioeng Biotechnol
. 2023 Jul;
11:1207576.
PMID: 37409169
Adoptive transfer of T cells modified to express chimeric antigenic receptors (CAR) has emerged as a solution to cure refractory malignancies. However, although CAR T cell treatment of haematological cancers...